Vnitr Lek 2020, 66(4):e5-e6 | DOI: 10.36290/vnl.2020.073

Léčba pacientů s chronickou myeloidní leukemií - nečekaný anebo očekávaný průnik onkologie a vnitřního lékařství?

Daniela Žáčková
Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice

Published: June 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Žáčková D. Léčba pacientů s chronickou myeloidní leukemií - nečekaný anebo očekávaný průnik onkologie a vnitřního lékařství? Vnitr Lek. 2020;66(4):e5-6. doi: 10.36290/vnl.2020.073.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bower H, Björkholm M, Dickman PW, et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 2016; 34: 2851-2857. Go to original source... Go to PubMed...
    2. Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029-1035. Go to original source... Go to PubMed...
    3. Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014; 32: 424-430. Go to original source... Go to PubMed...
    4. Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018; 19: 747-757. Go to original source... Go to PubMed...
    5. Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 2017; 31: 1525-1531. Go to original source... Go to PubMed...
    6. Sekhri A, Liu D, Rasul M, et al. Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation. Leuk Res 2009; 33: 1291-1293. Go to original source... Go to PubMed...
    7. Slezáková K, Mistrík M, Bátorová A. Súčasné možnosti liečby BCR-ABL1 pozitívnej chronickej myelocytovej leukémie u dospelých pacientov. Vnitř Lek 2020; 66(4): 214-224.. Go to original source... Go to PubMed...
    8. Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016; 34: 2333-2340. Go to original source... Go to PubMed...
    9. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132: 393-404. Go to original source... Go to PubMed...
    10. Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044-1054. Go to original source... Go to PubMed...
    11. Racil Z, Koritakova E, Sacha T, et al. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Am J Hematol 2018; 93: E342-E345. Go to original source... Go to PubMed...
    12. Medeiros BC, Possick J, Fradley M. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia Strategies for monitoring, detecting, and managing. Blood Rev 2018; 32: 289-299. Go to original source... Go to PubMed...
    13. Steegmann JL, Baccarani M, Breccia M, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment chronic myeloid leukaemia. Leukemia 2016; 30: 1648-1671. Go to original source... Go to PubMed...
    14. Simara P, Stejskal S, Koutna I, et al. Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition. Am J Hematol 2013; 88: 385-393. Go to original source... Go to PubMed...
    15. Faber E, Divoká M, Skoumalová I, et al. A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment. Leuk Lymphoma 2016; 57: 370-375. Go to original source... Go to PubMed...
    16. La Rosée P, Martiat P, Leitner A, et al. Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol 2013; 92: 1345-1350. Go to original source... Go to PubMed...
    17. Naqvi K, Jabbour E, Skinner J, et al. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2018; 124: 2740-2747. Go to original source... Go to PubMed...
    18. Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol 2017; 4: e310-e316. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.